Chinese Drug Ribupatide Shows Greater Weight Loss Than Wegovy in Clinical Trial
Clinical trial results indicate that ribupatide, an experimental weight-loss medication developed by Chinese pharmaceutical company Hengrui, enabled participants to shed nearly 18% of their body weight within 48 weeks. The findings suggest the drug may outperform established GLP-1 treatments like Wegovy in efficacy and speed.
Clinical trial data released this week indicate that ribupatide, an experimental weight-loss medication developed by Chinese pharmaceutical giant Hengrui, enabled participants to shed nearly 18% of their body weight within 48 weeks. The findings suggest the drug may outperform established GLP-1 treatments like Wegovy in both efficacy and speed.
The results come from a 48-week study conducted by researchers at Fudan University in Shanghai. The trial recruited 567 adults classified as overweight or obese, dividing them into four groups. Three groups received weekly injections of ribupatide at doses of 2 milligrams, 4 milligrams, and 6 milligrams, while the fourth group received a placebo.
All participants followed a lifestyle program that included dietary counseling and recommendations for at least 150 minutes of moderate exercise per week. After 48 weeks, those taking the lowest dose of ribupatide had lost an average of 10.7% of their starting body weight. Participants on the 4-milligram dose shed 16.4%, while those receiving the highest dose lost 17.7%.
These figures place ribupatide in direct competition with leading GLP-1 drugs. In a separate clinical trial, individuals taking a 2.4 mg dose of Wegovy lost an average of 14.9% of their body weight over a longer period of 68 weeks. The ribupatide results were achieved in less time and at higher percentages.
Study authors noted that weight loss among participants taking the two highest doses had not yet plateaued by the end of the 11-month study, suggesting potential for further reduction with extended treatment.
Beyond weight reduction, the drug demonstrated additional health benefits. Although none of the participants had diabetes, researchers observed reductions in blood sugar levels, as well as improvements in blood pressure and cholesterol. Waist measurements also decreased significantly, dropping by between 9 and 14 centimeters for ribupatide users compared to just 2.5 centimeters for the placebo group. Abdominal fat reduction is clinically significant due to its link with heart disease and other metabolic disorders.
Ribupatide functions by mimicking two hormones naturally produced in the gut that regulate appetite, digestion, and blood sugar. It shares a similar mechanism with Eli Lilly’s blockbuster drugs Mounjaro and Zepbound but has been engineered to bind more tightly to its targets and remain active in the body longer.
The drug was associated with familiar side effects common to GLP-1 medications, including nausea, vomiting, and diarrhea. Researchers reported that these symptoms were generally mild to moderate and occurred most frequently as participants increased their dosage.
Hengrui has partnered with US biotech firm Kailera Therapeutics to bring ribupatide to markets outside of China. The trial results arrive amid a growing demand for pharmacological obesity treatments, particularly in the United States, where approximately 40% of adults have obesity and over 21% of children and teenagers aged 2 to 19 are affected.
A September Gallup survey highlighted the rapid adoption of these medications, finding that 11% of US adults were currently taking a GLP-1 medication for weight loss, up from 3% in 2024. Overall, 15% of respondents reported having taken one of these drugs at some point, marking a nine percentage-point increase in just two years.
J.Alaqanone--DT